Paper
Dalton Transactions
tory activity of the complexes is closely related to their spatial
arrangements, which decide their interaction modes with the
LOX-1. The complex 1 that contains two mef ligands inhibits
9 J. E. Weder, C. T. Dillon, T. W. Hambley, B. J. Kennedy,
P. A. Lay, J. R. Biffin, H. L. Regtop and N. M. Davies, Coord.
Chem. Rev., 2002, 232, 95–126.
the enzyme activity competitively, while the bulky and low sym- 10 C. T. Dillon, T. W. Hambley, B. J. Kennedy, P. A. Lay,
metry complexes 2–3 tend to inhibit the enzyme activity un-
competitively. The computer docking results of the three com-
Q. D. Zhou, N. M. Davies, J. R. Biffin and H. L. Regtop,
Chem. Res. Toxicol., 2003, 16, 28–37.
plexes and the ligand mef with the LOX-1 are highly consistent 11 M. Konstandinidou, A. Kourounakis, M. Yiangou,
with the experimental results. The smaller size metal com-
plexes and the ligand itself are likely to bind competitively at
L. Hadjipetrou, D. Kovala-Demertzi, S. Hadjikakou and
M. Demertzis, J. Inorg. Biochem., 1998, 70, 63–69.
the substrate binding site, while the bulky complexes cannot 12 A. S. Fernandes, J. Gaspar, M. F. Cabral, C. Caneriras,
enter the substrate binding site, and thus inhibit the enzyme
activity un-competitively via binding to the enzyme at different
R. Guedes, J. Rueff, M. Castro, J. Costa and N. G. Oliverira,
J. Inorg. Biochem., 2007, 101, 849–858.
sites. The anti-oxidant activity of the Mn-mef complexes is also 13 C. V. Winder, J. Wax, L. Scotti, R. A. Scherrer, E. M. Jones
improved compared to the parent drug, which is apparently and F. W. Short, J. Pharmacol. Exp. Ther., 1962, 138, 405–413.
originated from the metal centre. The coordination of mef to 14 D. Kovala-Demertzi, D. Hadjipavlou-Litina, M. Staninska,
manganese ions improves the anti-inflammatory activity of
mef by enhancing its LOX-1 inhibitory activity, and/or increas-
A. Primikiri, C. Kotoglou and M. A. Demertzis, J. Enzyme
Inhib. Med. Chem., 2009, 24, 742–752.
ing its anti-oxidant ability via the manganese centre. We 15 F. Dimiza, A. N. Papadopoulos, V. Tangoulis, V. Psycharis,
demonstrated that metal-NSAID complexes are better anti-
inflammatory drug candidates than NSAIDs, because they have
C. P. Raptopoulou, D. P. Kessissoglou and G. Psomas,
Dalton Trans., 2010, 39, 4517–4528.
unique structures that could interact with the target enzymes 16 F. Dimiza, S. Fountoulaki, N. P. Athanasios,
more specifically. In addition, metal ions introduce extra anti-
oxidant activity to metal-NSAID complexes.
C. A. Kontogiorgis, V. Tangoulis, C. P. Raptopoulou,
V. Psycharis, A. Terzis, D. P. Kessissoglou and G. Psomas,
Dalton Trans., 2011, 40, 8555–8568.
17 V. Dokorou, A. Primikiri and D. Kovala-Demertzi, J. Inorg.
Biochem., 2011, 105, 195–201.
18 B. P. Skowronska, R. Kaczorowska and T. Skowronski,
Environ. Pollut., 1997, 97, 65–69.
Acknowledgements
This research was carried out with financial support from the
National Science foundation of China (no. 21001044 and 19 D. Hamai and S. C. Bondy, Neurochem. Int., 2004, 44, 223–229.
31070742), the State Key Laboratory of Bioreactor Engineering 20 E. J. Underwood, Trace Element in Human Health and Animal
(no. 2060204), 111 Project (no. B07023), and the Shanghai
Committee of Science and Technology (no. 11DZ2260600).
Nutrition, Academic press, New York, 4th edn, 1977.
21 B. K. Wagnont and S. C. Jackels, Inorg. Chem., 1988, 28,
1923–1927.
22 B. Axelrod, T. M. Cheesbrough and S. Laakso, Methods
Enzymol., 1981, 71, 441–451.
23 W. Minor, J. Steczko, B. Steczko, Z. Otwinowski, J. T. Bolin,
R. Walter and B. Axelrod, Biochemistry, 1996, 35, 10687–10701.
References
1 C. P. Duffy, C. J. Elliott, R. A. O’Connor, M. M. Heenan,
S. Coyle, I. M. Cleary, K. Kavanagh, S. Verhaegen, 24 R. Thomsen and M. H. Christensen, J. Med. Chem., 2006,
C. M. O’Loughlin, R. NicAmhlaoibh and M. Clynes,
Eur. J. Cancer, 1998, 34, 1250–1259.
2 F. Catella-Lawson, M. P. Reilly, S. C. Kapoor,
A. J. Cucchiara, S. Demarco, B. Tournier, S. N. Vyas and
G. A. Fitzgrerald, N. Engl. J. Med., 2001, 345, 1809–1817.
49, 3315–3321.
25 E. Vrontaki, G. Leonis, M. G. Papadopoulos, M. Simcic,
S. G. Grdadolnik, A. Afantitis, G. Melagraki, S. K.
Hadjikakou and T. Mavromoustakos, J. Chem. Inf. Model.,
2012, 52, 3293–3301.
3 J. R. Vane and Regina M. Botting, Am. J. Med., 1998, 104, 26 M. Saldias, V. Paredes-Garcia, A. Vega, W. Cañon
2S–8S.
Mancisidor, F. E. Le, D. V. Yazigi and E. Spodine, Poly-
hedron, 2012, 41, 120–126.
27 X. J. Jiang, H. Liu, B. Zheng and J. Y. Zhang, Dalton Trans.,
2009, 8714–8723.
28 R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald,
R. A. Stegeman, J. Y. Pak, D. Gildehaus, J. M. Iyashir,
T. D. Penning, K. Seibert, P. C. Isakson and W. C. Stallings,
Nature, 1996, 384, 644–648.
29 S. Fiorucci, R. Meli, M. Bucci and G. Cirino, Biochem.
Pharmacol., 2001, 62, 1433–1438.
4 L. A. G. Rodriguez, Clin. Exp. Rheumatol., 2001, 19,
S41–S44.
5 I. Bjamason, J. Hayllar, A. J. MacPherson and A. S. Ressell,
Gastroenterology, 1993, 104, 1832–1847.
6 P. Amadio, D. M. Cummings and P. Amadio, Postgrad.
Med., 1993, 93, 73–97.
7 N. Ouyang, P. Ji and J. L. Williams, Int. J. Oncol., 2012, 42,
643–650.
8 M. Elkady, R. Nieß, A. M. Schaible, J. Bauer, S. Luderer,
G. Ambrosi, O. Werz and S. A. Laufer, J. Med. Chem., 2012, 30 V. C. Ruddat, S. Whitman, T. R. Holman and
55, 8958–8962.
C. F. Bernasconi, Biochemistry, 2003, 42, 4172–4178.
10938 | Dalton Trans., 2014, 43, 10930–10939
This journal is © The Royal Society of Chemistry 2014